AI Engines For more Details: Perplexity Kagi Labs You
Antihistaminic Effects: Pheniramine maleate blocks the action of histamine, a substance in the body that causes allergic symptoms such as itching, sneezing, runny nose, and watery eyes. By inhibiting histamine receptors, pheniramine helps alleviate these symptoms.
Allergic Rhinitis: Pheniramine maleate is commonly used to treat symptoms of allergic rhinitis, including nasal congestion, itching, sneezing, and runny nose caused by allergens such as pollen, dust mites, and pet dander.
Hives (Urticaria): Pheniramine may also be used to relieve itching and reduce the size and number of hives or welts associated with allergic reactions.
Conjunctivitis: Pheniramine maleate eye drops are used to relieve itching and redness associated with allergic conjunctivitis (eye allergies).
Common Cold: Pheniramine maleate is sometimes included in over-the-counter cold and flu medications to alleviate symptoms such as runny nose, sneezing, and watery eyes.
Sedation: Pheniramine is a first-generation antihistamine that can cause sedation and drowsiness, particularly at higher doses or when combined with other medications that have sedative effects. This sedative effect may be desirable for individuals experiencing insomnia due to allergic symptoms but can be problematic for those needing to remain alert.
Dry Mouth: Pheniramine may cause dry mouth or xerostomia as a side effect. Patients should stay hydrated and consider using sugar-free candies or gum to alleviate this symptom.
Blurred Vision: Pheniramine may cause temporary blurred vision or difficulty focusing, particularly at higher doses. Patients should avoid activities such as driving or operating machinery if their vision is affected.
Urinary Retention: Pheniramine can cause urinary retention, especially in men with prostatic hypertrophy or individuals with bladder problems. Patients should be cautious and seek medical advice if they experience difficulty urinating.
Gastrointestinal Effects: Gastrointestinal side effects such as nausea, vomiting, and constipation may occur with pheniramine use, although they are less common compared to first-generation antihistamines like diphenhydramine.
Interactions: Pheniramine may interact with other medications, including central nervous system depressants, alcohol, and certain antidepressants or antipsychotics, leading to additive sedative effects. Patients should consult their healthcare provider before combining pheniramine with other medications.
Rank | Probiotic | Impact |
---|---|---|
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
Acne | 0.4 | -0.4 | |
ADHD | 4.7 | 0.9 | 4.22 |
Age-Related Macular Degeneration and Glaucoma | 1 | 0.4 | 1.5 |
Allergic Rhinitis (Hay Fever) | 2.2 | 2 | 0.1 |
Allergies | 6.2 | 2.2 | 1.82 |
Allergy to milk products | 0.8 | 0.8 | 0 |
Alopecia (Hair Loss) | 2.2 | 2.2 | |
Alzheimer's disease | 2.8 | 8.1 | -1.89 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.4 | 0.1 | 33 |
Ankylosing spondylitis | 4.3 | 1.8 | 1.39 |
Anorexia Nervosa | 0.4 | 2.8 | -6 |
Antiphospholipid syndrome (APS) | 2.2 | 0.3 | 6.33 |
Asthma | 1.7 | 0.8 | 1.13 |
Atherosclerosis | 0.9 | 2.4 | -1.67 |
Atrial fibrillation | 4.1 | 2.4 | 0.71 |
Autism | 12 | 11.2 | 0.07 |
Barrett esophagus cancer | 0.1 | 0.5 | -4 |
benign prostatic hyperplasia | 0 | 0 | |
Bipolar Disorder | 1 | 1.5 | -0.5 |
Brain Trauma | 0.9 | 0.8 | 0.13 |
Carcinoma | 4 | 2.8 | 0.43 |
Celiac Disease | 2 | 4.1 | -1.05 |
Cerebral Palsy | 1.4 | 1.3 | 0.08 |
Chronic Fatigue Syndrome | 6.5 | 7.4 | -0.14 |
Chronic Kidney Disease | 3.1 | 3 | 0.03 |
Chronic Lyme | 0.8 | -0.8 | |
Chronic Obstructive Pulmonary Disease (COPD) | 2.4 | 1.5 | 0.6 |
Chronic Urticaria (Hives) | 1.1 | 1.8 | -0.64 |
Coagulation / Micro clot triggering bacteria | 0.9 | 1.5 | -0.67 |
Colorectal Cancer | 3.5 | 1.4 | 1.5 |
Constipation | 1.8 | 1 | 0.8 |
Coronary artery disease | 2 | 1.1 | 0.82 |
COVID-19 | 10.9 | 15.9 | -0.46 |
Crohn's Disease | 7.9 | 7 | 0.13 |
cystic fibrosis | 0.1 | 1.2 | -11 |
deep vein thrombosis | 0.1 | 1 | -9 |
Depression | 12.1 | 9.2 | 0.32 |
Dermatomyositis | 0.5 | 0.4 | 0.25 |
Eczema | 1.1 | 3 | -1.73 |
Endometriosis | 3.1 | 0.8 | 2.88 |
Eosinophilic Esophagitis | 0.1 | -0.1 | |
Epilepsy | 2.9 | 1.5 | 0.93 |
Fibromyalgia | 2.7 | 4.2 | -0.56 |
Functional constipation / chronic idiopathic constipation | 5.8 | 5.1 | 0.14 |
gallstone disease (gsd) | 2 | 0.9 | 1.22 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.8 | 1.5 | 0.2 |
Generalized anxiety disorder | 1.6 | 2.6 | -0.63 |
giant cell arteritis | 0.5 | -0.5 | |
Glioblastoma | 0.5 | -0.5 | |
Gout | 0.5 | -0.5 | |
Graves' disease | 1.5 | 2 | -0.33 |
Halitosis | 0.3 | 0.5 | -0.67 |
Hashimoto's thyroiditis | 3.2 | 1 | 2.2 |
Hidradenitis Suppurativa | 0.8 | 0.1 | 7 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 3.9 | 1.5 | 1.6 |
hypercholesterolemia (High Cholesterol) | 0.7 | 0.7 | |
hyperglycemia | 0 | 1.5 | 0 |
Hyperlipidemia (High Blood Fats) | 0.9 | 0.5 | 0.8 |
hypersomnia | 0.8 | -0.8 | |
hypertension (High Blood Pressure | 2 | 6.1 | -2.05 |
Hypothyroidism | 1.8 | -1.8 | |
Hypoxia | 0.6 | 0.6 | |
IgA nephropathy (IgAN) | 5.7 | -5.7 | |
Inflammatory Bowel Disease | 5.2 | 10.1 | -0.94 |
Insomnia | 1.2 | 1.3 | -0.08 |
Intelligence | 2 | 1 | 1 |
Intracranial aneurysms | 1.1 | 0.5 | 1.2 |
Irritable Bowel Syndrome | 2.7 | 4.1 | -0.52 |
Liver Cirrhosis | 4.6 | 3.5 | 0.31 |
Long COVID | 9.5 | 10.4 | -0.09 |
Low bone mineral density | 1.5 | -1.5 | |
Lung Cancer | 0.2 | 1 | -4 |
ME/CFS with IBS | 1.9 | 3.7 | -0.95 |
ME/CFS without IBS | 3.4 | 2.9 | 0.17 |
Menopause | 1.7 | 1.7 | |
Metabolic Syndrome | 8.5 | 10.1 | -0.19 |
Mood Disorders | 14.5 | 9.6 | 0.51 |
multiple chemical sensitivity [MCS] | 1.4 | 0.5 | 1.8 |
Multiple Sclerosis | 6.6 | 7.6 | -0.15 |
Multiple system atrophy (MSA) | 2 | 0.9 | 1.22 |
Neuropathy (all types) | 1 | 0 | 0 |
neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.5 | 6 | -0.71 |
NonCeliac Gluten Sensitivity | 0.4 | -0.4 | |
Obesity | 10.5 | 4.8 | 1.19 |
obsessive-compulsive disorder | 6.5 | 5.9 | 0.1 |
Osteoarthritis | 2.6 | 2.6 | |
Osteoporosis | 1.3 | 0.8 | 0.63 |
pancreatic cancer | 0.7 | 0.7 | |
Parkinson's Disease | 3 | 4.8 | -0.6 |
Polycystic ovary syndrome | 2.6 | 1.6 | 0.63 |
Postural orthostatic tachycardia syndrome | 0.5 | 0.9 | -0.8 |
Premenstrual dysphoric disorder | 1.4 | 0.4 | 2.5 |
primary biliary cholangitis | 0.5 | 1.5 | -2 |
Psoriasis | 4.7 | 3.4 | 0.38 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 8.3 | 4.2 | 0.98 |
Rosacea | 1.4 | 1 | 0.4 |
Schizophrenia | 7.7 | 2.4 | 2.21 |
scoliosis | 0.5 | 1.3 | -1.6 |
Sjögren syndrome | 2.8 | 4.2 | -0.5 |
Sleep Apnea | 1.4 | 2.2 | -0.57 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.5 | 0.9 | -0.8 |
Stress / posttraumatic stress disorder | 2.6 | 3 | -0.15 |
Systemic Lupus Erythematosus | 4.9 | 2.1 | 1.33 |
Tic Disorder | 1.2 | 2.5 | -1.08 |
Tourette syndrome | 0.3 | -0.3 | |
Type 1 Diabetes | 3.4 | 3.6 | -0.06 |
Type 2 Diabetes | 9 | 7.8 | 0.15 |
Ulcerative colitis | 3.1 | 6.1 | -0.97 |
Unhealthy Ageing | 7.7 | 2.6 | 1.96 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.